Back to top
more

Gain Therapeutics (GANX)

(Delayed Data from NSDQ)

$1.75 USD

1.75
437,661

-0.29 (-14.04%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $1.74 -0.01 (-0.29%) 7:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why

by Zacks Equity Research

Gain Therapeutics (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates

by Zacks Equity Research

Adherex Technologies (FENC) delivered earnings and revenue surprises of -16.33% and 142.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Gain Therapeutics (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Gain Therapeutics (GANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)

by Zacks Equity Research

Gain Therapeutics (GANX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?

by Zacks Equity Research

Alpine Immune Sciences (ALPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Gain Therapeutics, Inc. (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Gain Therapeutics, Inc. (GANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock

by Zacks Equity Research

Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.

Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -87.88% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -3.85% and 69.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -7.50% and 175%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Scynexis (SCYX) delivered earnings and revenue surprises of 10.71% and 24.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of -13.33% and 2.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Gain Therapeutics, Inc. (GANX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Gain Therapeutics, Inc. (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -200% and 2.26%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 10.17% and 42.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 4.76% and 12.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of 4.55% and 34.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 3.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -22.86% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Gain Therapeutics, Inc. (GANX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.65% and 25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Brickell (BBI) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Brickell (BBI) delivered earnings and revenue surprises of -33.33% and 52.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?